The immunohistochemical (IHC) staining of mouse tissue sections using antibodies of mouse origin can result in high nonspecific background due to the staining of endogenous immunoglobulins (Igs) by enzyme-conjugated secondary antibodies. In order to obviate this issue, we developed a chimeric mouse-human anti-p53 monoclonal antibody (MH242) by grafting the variable regions of a known mouse antibody into a human Ig scaffold. This facilitated use of an anti-human secondary antibody, and resulted in near-zero background when compared with its parental mouse monoclonal antibody (PAb242). Furthermore, the chimeric antibody enabled reproducible detection of mutant p53 (homozygous R172H) expression in mouse tissue, an observation hitherto largely equivocal based on the use of existing antibodies. The approach we describe leads to the generation of tractable antibody reagents, whose integrity can be readily verified through DNA sequencing of expressor plasmids. The wide-spread adoption of such 'digitized' antibodies should reduce experimental disparities that can commonly arise through variations in antibody quality.
Introduction
The immunohistochemical (IHC) staining technique facilitates visual detection of antigen(s)-of-interest on tissue sections (Coons et al., 1941) . In addition to being widely used for research purposes, IHC has been applied in the diagnosis and prognosis of disease, in the selection of personalized therapeutic regimes and in understanding the pathogenesis of disease (Leong and Leong, 2006; Teruya-Feldstein, 2010; Ramos-Vara and Miller, 2014) .
IHC relies on antibody-mediated detection of target, and is therefore prone to reproducibility issues that may confound analysis. These can be inherent, and often relate to innate qualities of the antibody reagent used such as specificity, affinity and purity. Systematic variation arising from differing protocols, choice of secondary antibody and signal amplification/detection method can also lead to discordancy.
Various detection methodologies have been reported in studies using IHC (Fung et al., 1992; Hierck et al., 1994; Sabattini et al., 1998; Ramos-Vara, 2005; Ramos-Vara and Miller, 2014) . The 'indirect' and the 'polymeric two-step' detection systems are commonly used. Both are two-step processes: an unlabeled primary antibody that recognizes the target antigen is first applied on the tissue section, followed by a species-specific secondary antibody conjugated with a label that can generate detectable signal. Each species-specific secondary antibody in the polymeric detection system is linked with multiple labels via conjugation to a polymer (Ramos-Vara and Miller, 2014) . The label in these systems may be enzymatic [e.g. horseradish peroxidase (HRP) and alkaline phosphatase] or a fluorophore [e.g. fluorescein isothiocyanate]. Both systems offer increased sensitivity in the form of signal amplification via the addition of secondary antibodies. The biggest disadvantage, however, is the simultaneous increase in background signal mainly due to the binding of secondary antibodies to endogenous immunoglobulin (Ig) present in the tissue sections. This is especially the case when labeled anti-mouse secondary antibodies are used with primary mouse monoclonal antibodies on mouse (and rat) tissue sections (Fung et al., 1992; Hierck et al., 1994; Ramos-Vara, 2005; Ramos-Vara and Miller, 2014; Ward and Rehg, 2014) .
In order to reduce this common source of undesirable background signal, we generated a hybrid antibody comprising the elucidated variable regions derived from an anti-p53 mouse monoclonal antibody grafted into a human IgG scaffold. The p53 tumor suppressor protein is an intensely explored target for cancer therapy (Hoe et al., 2014) and is widely studied in numerous mouse models (Lozano, 2007 (Lozano, , 2010 . The engineered antibody enabled usage of secondary antibodies that do not recognize endogenous mouse IgG, markedly reducing background signal. It represents a functional, best in class mouse-human chimera against mouse p53, particularly suited for the IHC staining of paraffin-embedded mouse tissue sections using indirect detection systems. This hybrid antibody is effectively 'digitized' by the availability of complete sequence information, thus rendering it fully compliant with the increasing demands for experimental reproducibility and tractable recombinant antibody reagents (Bradbury and Pluckthun, 2015) .
Materials and methods
Note that the sequences of all oligonucleotides may be found in the Supplementary Table SII.
Cloning 242scFv from PAb242 hybridoma cells
Total RNA was extracted from the PAb242 hybridoma cell line using TRIzol (Invitrogen), chloroform (BDH) and 75% (v/v) ethanol, then purified using the QIAGEN RNeasy kit. cDNA was obtained by reverse transcription (RT) using oligo(dT) (Fermentas), according to the manufacturer's 'Fermentas RevertAid H Minus RTase' protocol. One microgram of this product was used as template for subsequent cloning of the variable heavy and light chains of the PAb242 antibody.
The variable heavy chain was amplified using the KAPA HiFi DNA Polymerase (Kapa Biosystems) with 0.3 mM dNTPs and 0.1 µM each of the CH1 and VH1 to VH7 (pre-mixed in equi-molar ratios) primers [ primer sequences were taken from a previous study (Essono et al., 2003) ]. Cycling conditions were as follow: 95°C for 3 min, 98°C for 20 s, 65°C for 30 s, 72°C for 15 s, steps 2-4 were repeated for a total of 30 cycles, before a final extension was done at 72°C for 5 min. This polymerase chain reaction (PCR) product was purified before being cloned for DNA sequencing using the M13(-20)-F primer.
The variable light chain was amplified using the BIOTAQ™ DNA polymerase with 0.2 mM dNTPs and 0.4 µM each of the mK and mKc primers. Cycling conditions were as follow: 94°C for 3 min, 94°C for 40 s, 50°C annealing for 40 s, 72°C for 1 min, steps 2-4 were repeated for a total of 30 cycles. This PCR product was column-purified before being cloned. Colonies were screened for contaminating nonprotein producing sp2 light chain DNA sequences using the XSp2_qPCR_2F and XSp2_qPCR_R primers (designed by Dr Julin Wong, p53
Laboratory, A*STAR) before being picked for sequencing using the M13(-20)-F primer.
All variable heavy and light chain clones elucidated were then cloned into the pIT2 phagemid vector (Tomlinson I and J, MRC HGMP Resource Centre) using appropriately designed primers and expressed as phage-displayed scFv antibodies. Growth supernatants of each scFv antibody were harvested for enzyme-linked immunosorbent assay (ELISA) functional test using purified recombinant p53 proteins.
MH242 antibody cloning, expression and purification
PAb242 variable chains were prepared for In-Fusion HD cloning via PCR, using primers and conditions listed in Supplementary table SI, and cloned according to the manufacturer's protocol into separate modified pTT5 vectors containing human IgG1 constant region scaffolds for the heavy (digested with SalI and BstEII enzymes) and light (SalI and NotI) chains.
The MH242 heavy pTT5 and MH242 kappa pTT5 plasmids were co-transfected into HEK293-6e cells using 293fectin (Invitrogen), following the manufacturer's protocol, except for the following changes for the HEK293-6e cells: (i) instead of FreeStyle 293 Expression Medium, cells were transfected and grown in 'complete medium'-F17 medium supplemented with 1× Glutamax, 0.045% (w/v) Pluronic acid (Invitrogen) and 0.2 mM Valproic acid sodium salt; (ii) cells were transfected at the recommended 1 × 10 6 cells/ml concentration but diluted with complete medium to 0.5 × 10 6 cells/ml 4 h post-transfection; (iii) cells were grown in 5% (instead of 8%) CO 2 environment; (iv) MH242 antibody was harvested after 8 days of culture, instead of the recommended 48 h. Culture supernatant was purified using protein G agarose beads (Millipore) packed into polypropylene columns (Qiagen). Captured MH242 antibody was eluted from the beads with 0.1 M glycine pH 2.5 (1st Base) and immediately neutralized in 1/5th volume of 1 M Tris (1st Base) pH 8. Fractions containing the antibodies-assayed using Bradford protein quantification (Bio-Rad) colorimetric testwere pooled and buffer exchanged into phosphate-buffered saline (PBS) using a centrifugal filter unit with 100 kDa molecular weight cut-off (Sartorius). The purified MH242 antibody was quantified on a spectrophotometer at 280 nm wavelength. Sodium azide was added to a final concentration of 0.02% (w/v) as preservative. Purified MH242 antibody was tested in ELISA assays.
PCR
Generally, PCRs were carried out using the BIOTAQ™ DNA polymerase kit (Bioline), setup as follows: NH 4 buffer (1×), 1.5 mM magnesium chloride, 1 U BIOTAQ™ DNA polymerase, 0.2 mM dNTP mix, 0.5 µM of each primer, 5-35 ng of DNA template, topped up to 30 µl using molecular-grade water. Thermal cycling conditions were as follows: 95°C for 3 min, 95°C for 5 s, 60°C for 30 s, 72°C for 1 min, steps 2-4 for a total of 20-30 cycles. This was followed by a 72°C for 5 min step.
DNA sequencing
DNA templates were sequenced either by the Institute of Molecular and Cell Biology DNA sequencing facilities (IMCB DSF, A*STAR) or by 1st Base DNA sequencing facilities (Singapore).
Enzyme-linked immunosorbent assay
Fifty microliters per well of either 0.03 µg/µl of GST-tagged fulllength mouse p53 or 0.003 µg/µl of His-tagged full-length or N-terminus-only human p53 proteins were coated onto Maxisorp plates (Nunc) overnight in a humidity chamber at 4°C. Plates were washed with PBS, blocked with MT [5% milk in PBS supplemented with 0.1% Tween 20 (PBST)] for 2 h at room temperature with gentle agitation then washed with PBST. Primary antibodies diluted into MT were added for 1-2 h at room temperature with gentle agitation. Primary antibodies tested include phage-displayed scFv in phage supernatant at neat, 1:10, 1:100, 1:1000 dilutions, and purified antibodies at 1:10, 1:100, 1:1000 (1:10 000, 1:100 000) (which translates to 0.1, 0.01, 0.001 (0.0001, 0.00001) mg/ml concentrations) dilutions. Plates were washed with PBST then incubated with HRP-conjugated secondary antibodies diluted into PBS for 1 h with gentle agitation at room temperature. Secondary antibodies used include 1:1000 diluted rabbit anti-mouse immunoglobulin (Dako), 1:2000 diluted goat anti-human immunoglobulins (Jackson ImmunoResearch), and 1:1000 diluted mouse anti-M13 (GE Healthcare) which targets the bacteriophage M13 major coat protein product of gene VIII (gp8). Plates were washed with PBST then PBS. Protein interaction signals were detected using the TMB One Solution (Promega), followed by an equivolume of sulfuric acid (0.5 M). Signals were measured at 450 nm wavelength using the EnVision Reader.
Western blot
Endogenous proteins were harvested from tissue-cultured cells by scraping into PBS on ice then pelleted at 1000 rpm for 5 min at 4°C. The cell pellet was washed with once with cold PBS then lysed with RIPA buffer (250 mM of Tris-HCl buffer, pH 7.4-8.0, supplemented with 750 mM NaCl, 5% (v/v) NP-40 and protease inhibitor ('cOmplete, mini', EDTA-free protease inhibitor cocktail tablets; Roche). Total protein concentrations were quantified using the BCA assay kit (Pierce Biotechnology), according to the manufacturer's 'Microplate Procedure' protocol.
Using a Bolt 4-12% Bis-Tris Plus gel, 1, 0.3, 0.1, 0.03 and 0.01 µg of the purified human p53 protein (and equivalent amounts of purified mouse p53 protein) or 25 µg of the endogenous proteins were separated in MOPS running buffer. Proteins were transferred onto the PVDF membrane (iBlot Transfer Stacks, Invitrogen) using the iBlot Dry Blotting System (Invitrogen). Membranes were blocked with MT. Primary antibodies were incubated overnight at 4°C, at 1 µg/ml or according to the manufacturers' recommendations. Primary antibodies include: p53 (1C12) Mouse mAb (Cell Signaling), anti-GST (Abcam), anti-His (santa cruz), DO-1, PAb242 (gifts from Dr Vojtesek, Czech Republic) and MH242 (self-made). Protein levels were detected using HRP-conjugated secondary antibodies (1 µg/ml of rabbit anti-mouse immunoglobulin, Dako; or 0.8 µg/ml of goat anti-mouse or anti-human IgG (Fcγ fragment specific), Jackson ImmunoResearch) with Amersham™ ECL™ Western Blotting Detection Reagent (GE Healthcare). Signal was detected using CL-XPosure™ Film (Thermo Scientific).
Immunohistochemical staining of paraffin-embedded sections
Note that serial tissue sections were used for each set of IHC experiment, unless otherwise stated.
Mouse intestines of p53 R172H/R172H genotype (with or without γ-ray irradiation) or p53 −/− genotype (with γ-ray irradiation) and mouse spleen of p53 R172H/R172H genotype (with γ-ray irradiation)
were processed into paraffin blocks by the Advanced Molecular Pathology Laboratory (AMPL), Institute of Molecular and Cell Biology. Wax sections at 5 µm were then collected onto slides (Leica Biosystems) and dried on a 50°C hot plate for 1 h. Sections were deparaffinized in xylene (ChemTech Trading) and rehydrated through descending percentages of ethanol (ChemTech Trading) to water. Tissue sections were heated with Target Retrieval Solution, pH9 (Dako) in the 2100 Antigen Retriever (Aptum Biologics) to expose the antigens, then rinsed thrice in PBS. Endogenous peroxidase was blocked with 2% (v/v) hydrogen peroxide (Merck) in PBS for 30 min, rinsed with water then PBS. Note that this blocking step was skipped in a set of spleen section samples to test for increased background signal when compared with spleen sections with endogenous peroxidase blocked. Sections were blocked with 10% (v/v) goat serum (Dako) in PBS for 1 h then incubated with primary antibodies at 4°C overnight. Primary antibodies used include: 1:400 diluted Ki67 (clone MM1; Novocastra, Leica), 1:100 or 1:200 diluted DO-1 (gift from Dr Vojtesek, Czech Republic), and 1:200 diluted PAb242 (gift from Dr Vojtesek, Czech Republic), all of mouse origins. Primary antibodies of nonmouse origins include: 1:500 diluted CM-5 (rabbit polyclonal, gift from Dr Vojtesek, Czech Republic) and 1:200 diluted MH242 (self-made). Sections were washed in running tap water then rinsed in PBS before being incubated with EnVision peroxidase labeled polymer conjugated to goat anti-mouse or anti-rabbit immunoglobulins (Dako; neat concentrations) or 1:100 diluted peroxidase labeled goat anti-mouse or anti-human IgG (Fcγ fragment specific) (Jackson Immuno Research). Antigen-antibody interaction was then visualized using 3,3′-diaminobenzidine as a substrate, and the sections were lightly counterstained with hematoxylin before dehydrating and mounting in Cytoseal 60 synthetic resin (Richard-Allan Scientific™, Fisher Scientific). Slides were imaged under bright field using the AxioImager (Zeiss) light microscope and analyzed with AxioVision Rel 4.8 software (Carl Zeiss AG).
Affinity constants (bio-layer interferometry)
The affinity constants of the PAb242 and MH242 antibodies against biotinylated mouse and human p53 peptides (mAg and hAg, respectively) were determined using bio-layer interferometry. Before the actual kinetics assays, optimization was done to determine the best peptide loading concentration to achieve 1:1 binding stoichiometry between the bound peptides and the antibody, and the best regeneration buffer(s) to reduce biosensor wastage.
Loading of both the Biotin-DO1 and Biotin-mu242 peptides onto the streptavidin-coated biosensors was optimized to achieve sufficient spacing between peptides for 1:1 interaction ratio with the antibodies during subsequent affinity kinetics runs. Both peptides were loaded at 1 µM concentrations using the following 'Basic Kinetic' conditions (Table I) for kinetics assays, with the maximum coating level controlled at 1.7 nm ± 10%.
To calculate affinity constants for the DO-1 and PAb242 antibodies, both antibodies were assayed in duplicates across the following concentrations: 0, 12.5, 25, 50, 100 and 200 nM, diluted using the Both initial baseline and dissociation were carried out using PBS.
'kinetics buffer' (PBS supplemented with 0.002% (v/v) Tween 20 and 0.01% (w/v) BSA), with the following 'Advanced Kinetics' run conditions (Table II) . Biosensors ( pre-loaded with the peptides and bound by respective antibodies) were regenerated for the subsequent kinetics assay, starting from the lowest to the highest antibody concentration. However, a newly coated biosensor was used for each set of antibody titrations.
Results and discussion
For the purpose of this study, the mouse monoclonal anti-p53 antibody, PAb242, was chosen as the source of variable regions targeting p53 (Yewdell et al., 1986) . The epitope of PAb242 has been mapped to the sequence 18 TFSGLWKLLP 27 in the N-terminal domain of mouse p53 (Yewdell et al., 1986; Lane et al., 1996) .
Cloning of PAb242 variable regions and primary characterization by phage ELISA
The candidate variable heavy chain gene was cloned from PAb242 hybridoma cells using the VH and CH1 (mouse) primers, respectively [from a previous study (Essono et al., 2003) ]. Variable light chain gene (7c4FL) was cloned using the mK and mKc primers (Wang et al., 2000) (Table III) . Phage ELISA was next used to validate the function of the cloned antibody variable region genes (Table III) . The 7c4FL candidate light chain and the variable light chain region from DO-1 were cloned into a phagemid vector, together with the candidate heavy chain. The phage-displayed scFv, negative control phage-displayed scFv (HB8525) and purified control antibodies (DO-1 and PAb242) were tested by ELISA to confirm their functionality and specificities. 242scFv (7c4FL) showed 4.36-fold increased preference for mouse over human p53 protein (Fig. 1, double asterisks) . This binding preference is also observed for PAb242, strongly suggesting that both the correct variable light (7c4FL) and heavy chains were cloned. A hybrid scFv (242H + DO1L), constructed by combining PAb242 variable heavy chain with the known DO-1 variable light chain, showed slight preference for mouse over human p53 protein (Fig. 1, single  asterisk) -an indication that the PAb242 heavy chain alone was able to shift antibody-antigen binding specificity.
Characterization of the mouse-human chimeric antibody, MH242
The variable heavy and light chains were next cloned into pTT5 human IgG1 scaffold vectors and expressed in HEK293 cells. Purified MH242 was first tested by ELISA using immobilized mouse or human p53 protein. Chimeric MH242 antibody retained the binding affinity and specificity of its parental antibody, preferentially binding mouse but not human p53 protein (Fig. 2) . Further, MH242 retained similar binding affinity across the concentration range tested (0-100 µg/ml).
The PAb242 and MH242 antibodies were next used for detection of recombinant mouse and human p53 proteins via Western blot. The DO-1 antibody (Fig. 3, blot A) was included as a positive control. As expected, PAb242 and MH242 (Fig. 3 , blots B and C) detected mouse but not human p53 protein. The blots indicated that MH242 was able to detect mouse p53 proteins at a lower amount (0.01 µg) than PAb242 (0.03 µg) when compared under similar experimental conditions (Fig. 3, compare blots B and C) . However, this difference may simply be due to a difference in sensitivities between the HRPconjugated rabbit anti-mouse and goat anti-human secondary antibodies used to respectively detect PAb242 and MH242.
Both PAb242 and MH242 detected denatured endogenous p53 protein in cell lines expressing mouse but not human p53 proteins (Fig. 4 blots C and D ). PAb242 and MH242 were able to detect highly expressed endogenous mouse p53 in the Clone 6 cell line ['C6'; a rat embryo fibroblast cell line co-transformed with a mouse p53 A135 V (Fig. 4 blots C and D, compare lane 9 with lanes 3 to 5, 7 and 8). ActD treatment was reported to increase cellular p53 protein levels (Kastan et al., 1991; Choong et al., 2009) . Positive control antibodies only detected their expected targets: DO-1 detected only endogenous human p53, while 1c12 detected endogenous p53 from both human and mouse cell lines (Fig. 4 blots A and B, respectively) . The affinity constants of the PAb242 and MH242 antibodies against the mAg peptide were 701 ± 173 and 919 ± 273 nM, respectively, indicating that the chimeric MH242 antibody retained similar binding affinity to parental PAb242 antibody ( Supplementary Fig. S1A and B). Both antibodies showed around 100-fold reduced affinity compared with that of DO-1 against human p53 peptide (KD = 8.0 ± 0.2 nM) ( Supplementary Fig. S1C ). This difference in binding affinities most likely explains the difference in detection limits of the PAb242, MH242 and DO-1 antibodies when used in Western blot assays (Fig. 4) . More experiments need to be done to determine if other antibody properties affect this detection limit in Western blot assays, and if the same properties apply for the same antibody in different assays.
Immunohistochemical staining
Optimization of pH for heat-induced epitope retrieval The pH used in heat-induced epitope retrieval (HIER) for mouse p53 protein was optimized using the polymeric immunoperoxidase detection method on paraffin-embedded mouse intestinal tissue sections. Tissues were harvested from mice with either (i) p53 R172H/R172H genotype and irradiated with γ-rays to induce p53 expression in the tissue (Fig. 5 , images 1-6) or (ii) p53 −/− genotype ( p53-null negative control tissue sections) (Fig. 5 , images 7 and 8). The mouse p53 R172H mutation was chosen as it is equivalent to the missense hot-spot mutation, R175H in human p53, found in many human cancers (Liu et al., 2000; Olive et al., 2004) . Also, missense point mutations in p53 often result in heightened p53 protein levels (O'Connor et al., 1997; Olive et al., 2004; Soussi, 2007) . Similarly, γ-irradiated samples were chosen as these typically show increased p53 protein levels (Komarova et al., 1997; Hoe et al., 2014) . Both PAb242 and CM5 (rabbit polyclonal) antibodies bind mouse p53 protein. The polyclonal CM5 binds multiple epitope sequences on the p53 protein, overlapping with those recognized by the PAb240, Fig. 1 ELISA to confirm that functional variable heavy and light chains were elucidated from parental PAb242. Averaged OD 450 readings was plotted for neat (1×; phage-displayed scFv; left panel) or 10-fold diluted (0.1 µg/µl; DO-1 and PAb242 control antibodies; right panel) antibody concentrations. scFv samples 242scFv and hybrid show higher preference for mouse over human p53 protein (double and single asterisks, respectively) (n = 2). PAb241, PAb242, PAb243, PAb248, DO-11 and ICA-9 monoclonal antibodies (Lane et al., 1996) . As CM5 has been used successfully for mouse p53 protein staining on identical sections (Goh et al., 2015) , it was used as a positive control in this experiment to indicate plausible locations of mouse p53 (deep-brown nuclear staining in Fig. 5 , images 1 and 2). DO-1 antibody that does not bind mouse p53 protein was included as a negative control (no deep-brown nuclear staining in Fig. 5 , images 5 and 6).
Comparing the sections processed using the pH 6 citrate and pH 9 Tris/EDTA antigen retrieval solutions (Fig. 5 , images 1 and 3 with 2 and 4, respectively), it was apparent that the mouse p53 antigen was more successfully retrieved using the pH 9 Tris/EDTA buffer. Sections stained by both the CM5 and PAb242 antibodies clearly revealed the location of p53 proteins in the nuclei of intestinal crypts at pH 9 (Fig. 5, images 2 and 4) . However, the nuclei were weakly stained when antigen retrieval was done at pH 6 (Fig. 5, images 1 and 3 ) HIER was thus carried out using the pH 9 Tris/EDTA buffer for downstream IHC assays.
MH242 IHC application trials
The chimeric mouse-human monoclonal MH242 requires an HRP-conjugated anti-human secondary antibody for IHC detection. As polymeric HRP-conjugated secondary antibody to human is not available, HRP-conjugated goat anti-human secondary antibody (and a similar HRP-conjugated goat anti-mouse secondary antibody) was used. Both secondary antibodies were first optimized against 100-fold diluted (10 µg/ml) PAb242 and MH242 antibodies on the paraffin-embedded, γ-ray irradiated p53 R172H/R172H mouse intestinal tissue sections to determine the optimal dilution for use on IHC sections. From this, 1:100 dilution of the HRP-conjugated secondary antibodies was selected for IHC staining experiments. Mouse intestinal tissue sections with p53 R172H/R172H (± γ-irradiation) or p53 −/− genotype were stained with PAb242, MH242, DO-1 or Ki67 (clone MM1) monoclonal antibodies. The Ki67 antibody stains an antigen located in the nucleus of actively proliferating cells. p53 protein, being a transcription factor involved in cell cycle regulation (Hoe et al., 2014) , is also located in the nucleus of actively dividing cells. Thus, positive staining with the Ki67 antibody (Fig. 6 , brown nuclear staining observed in panel 1) serves as an indication for the plausible location of p53. Goat serum (Fig. 6 , panels 3 and 4) was used to replace the primary antibodies as a control to indicate the amount of background staining on the sections caused mainly by the HRPconjugated anti-mouse secondary antibody. Sections stained with the mouse-origin PAb242 (Ki67 and DO-1) antibody and HRP-conjugated anti-mouse secondary antibody resulted in high background staining of endogenous mouse Ig found in the blood vessels (Fig. 6A, red arrows) . However, sections stained with the chimeric mouse-human MH242 visualized with HRPconjugated anti-human secondary antibodies remained free of background staining (Fig. 6A, black arrows) . In mouse intestinal tissues without γ-irradiation, background staining for PAb242 became noticeably more obvious due to the lower positive signal (Fig. 6B) .
MH242 was next used for the IHC staining of mouse spleen tissue with higher levels of endogenous Ig compared with mouse intestine. At a much higher level of endogenous mouse Ig, the chimeric mousehuman MH242 displayed improved signal: background staining ratios when compared with the parental PAb242 of mouse origin ( Supplementary Fig. S2A ). Background staining was further aggravated when endogenous peroxidase [ present in circulating macrophages and monocytes (Deimann, 1984) ] was not pre-blocked using hydrogen peroxide. However, MH242 still produced comparatively cleaner staining of mouse p53 proteins compared with PAb242 in the spleen tissue sections, despite the heightened background signal (Supplementary Fig. S2B ).
These results confirmed that the use of mouse-origin primary antibodies (indirectly) give rise to high background staining of endogenous mouse Ig and thus false-positive IHC staining results. This would confound analysis on the status of p53 in mouse tissue sections. Furthermore, tissue sections in both sets of experiments were harvested from normal, nondiseased mice. Under diseased conditions, endogenous Ig may travel out from blood vessels to the surrounding cells or site of infection as a natural defence reaction (Janeway et al., 2001; Greenfield, 2013) . The background staining of endogenous Ig by antimouse secondary antibodies under such scenarios would have been much higher than observed in this study. The lowering of background staining via the use of chimeric mouse-human primary antibodies would therefore be predictably more compelling when applied in mouse models of diseased states.
As mouse monoclonal antibodies are widely used in IHC assays, background binding by anti-mouse secondary antibody with endogenous Ig on mouse tissue sections is deemed a serious issue (Fung et al., 1992; Hierck et al., 1994; Ramos-Vara, 2005; Buchwalow and Böcker, 2010; Ramos-Vara and Miller, 2014; Ward and Rehg, 2014) . Methods have been actively sought to overcome this issue. These include: (i) the use of a direct detection method where the primary antibody is conjugated with a label for direct detection of the antigen of interest; (ii) using isotype-specific anti-mouse secondary antibody; (iii) pre-blocking endogenous Ig using nonlabeled antimouse secondary Fab fragments (Buchwalow and Böcker, 2010) and (iv) allowing the anti-mouse secondary antibody to bind to primary antibodies in solution, followed by the blocking of unbound secondary antibody paratope with mouse serum (contains a variety of mouse-origin primary antibodies) before applying the complex onto the mouse tissue sections (Fung et al.,, 1992; Hierck et al., 1994) .
To this array of techniques, we add the method of engineering a mouse-antigen specific monoclonal antibody of mouse origin into a chimeric mouse-human antibody. Using this method, antigen-detection need not be limited to the direct detection method with lower sensitivity; conventional anti-human secondary antibodies may be used for detection, and it may be used in combination with methods 3 and/or 4 highlighted above to further lower the background staining of endogenous Ig in mouse tissue sections.
As shown in this study, p53 R172H in mouse tissue was more successfully exposed at pH 9 when compared with pH 6 when detected using CM5, and PAb242 antibodies (Fig. 5) . A previous study using CM5 antibody and pH 6 for antigen exposure failed to detect mutant p53 R172H in the nuclei of intestinal crypts in paraffin-embedded Fig. 5 IHC staining using the PAb242 antibody (and various control antibodies) on paraffin-embedded mouse intestinal tissue sections with antigen retrieval done using pH 6 (images 1, 3, 5, 7) and 9 (images 2, 4, 6, 8) solutions. Mouse intestinal tissue sections were harvested from mice either with: (i) p53 R172H/R172H genotype (γ-irradiated to increase p53 expression) (images 1-6) or (ii) p53 −/− genotype ( p53-null) as negative control sections (images 7 and 8). Images taken using the AxioImager (Zeiss) light microscope with a 40× objective lens.
mouse intestinal tissue sections (Terzian et al., 2008) . Hence, the apparent nonreproducible observations in the presence (or absence) of homozygous mutant p53 proteins in mouse intestinal tissue sections may simply be due to the use of different staining protocols. Therefore, for reproducible observations and conclusions in future experiments, it would be beneficial to provide standardized protocols for all applicable assays (IHC and ELISA assays for the case of PAb242 and MH242) specific for each new antibody. This would support the recommendations of Bradbury and Pluckthun (2015) and Ramos-Vara et al. (2008) .
Conclusion
We have described MH242, an engineered chimeric antibody designed to reduce background signal in IHC applications. This antibody retained all characteristics of the parental antibody it was derived from. As a recombinant antibody, both sequence data, along with protocols for expression (and purification) and application of phagedisplayed 242scFv and full-length MH242 antibodies may be shared with other researchers to ensure experimental consistency. The use of this 'digitized' antibody, along with the optimized protocol, both supports the call for standardization of antibody reagents (Bradbury and Pluckthun, 2015) , and harmonization of IHC protocols (Ramos-Vara et al., 2008) .
Supplementary data
Supplementary data are available at PEDS online.
